Phreesia (NYSE:PHR) PT Raised to $34.00

Phreesia (NYSE:PHR) had its target price lifted by Robert W. Baird from $31.00 to $34.00 in a research note released on Friday morning, Benzinga reports. They currently have an outperform rating on the stock.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group reissued a buy rating and issued a $34.00 price target on shares of Phreesia in a research report on Thursday, September 5th. Truist Financial reaffirmed a buy rating and issued a $29.00 price objective on shares of Phreesia in a research report on Monday, July 1st. JMP Securities reaffirmed a market outperform rating and issued a $30.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. DA Davidson reaffirmed a buy rating and issued a $32.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. Finally, KeyCorp lowered their price objective on Phreesia from $27.00 to $25.00 and set an overweight rating on the stock in a research report on Thursday, July 11th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average target price of $30.23.

Phreesia Stock Performance

Shares of PHR opened at $23.91 on Friday. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average price is $23.44 and its 200-day moving average price is $22.75. Phreesia has a 52 week low of $12.05 and a 52 week high of $29.16. The stock has a market cap of $1.37 billion, a P/E ratio of -11.02 and a beta of 0.93.

Insider Buying and Selling at Phreesia

In other Phreesia news, SVP David Linetsky sold 1,820 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $23.74, for a total transaction of $43,206.80. Following the completion of the sale, the senior vice president now directly owns 202,218 shares in the company, valued at approximately $4,800,655.32. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, SVP David Linetsky sold 1,820 shares of the firm’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total value of $43,206.80. Following the transaction, the senior vice president now directly owns 202,218 shares of the company’s stock, valued at approximately $4,800,655.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Allison C. Hoffman sold 14,110 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $26.03, for a total value of $367,283.30. Following the completion of the transaction, the general counsel now directly owns 121,003 shares in the company, valued at $3,149,708.09. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,337 shares of company stock worth $736,750. Insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Phreesia

Institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC raised its holdings in Phreesia by 76.5% in the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock worth $64,000 after purchasing an additional 1,300 shares during the period. Russell Investments Group Ltd. raised its holdings in Phreesia by 5,462.3% in the 4th quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock worth $89,000 after purchasing an additional 3,769 shares during the period. EntryPoint Capital LLC bought a new position in Phreesia in the 1st quarter worth $169,000. Quadrature Capital Ltd bought a new position in Phreesia in the 1st quarter worth $202,000. Finally, Lombard Odier Asset Management USA Corp bought a new stake in Phreesia during the second quarter valued at about $202,000. 92.10% of the stock is owned by institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.